IRIS
ZAJA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.295
AS - Asia 3.945
EU - Europa 3.494
SA - Sud America 865
AF - Africa 71
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 7
Totale 21.694
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.164
SG - Singapore 1.779
UA - Ucraina 1.174
CN - Cina 983
BR - Brasile 718
DE - Germania 621
HK - Hong Kong 486
FI - Finlandia 419
IT - Italia 362
RU - Federazione Russa 282
SE - Svezia 254
VN - Vietnam 247
IE - Irlanda 186
TR - Turchia 122
CA - Canada 81
GB - Regno Unito 74
IN - India 64
KR - Corea 62
AR - Argentina 58
BD - Bangladesh 29
IQ - Iraq 29
IR - Iran 27
CO - Colombia 26
MX - Messico 26
ZA - Sudafrica 25
ID - Indonesia 22
BE - Belgio 19
JP - Giappone 19
EC - Ecuador 17
MA - Marocco 16
ES - Italia 15
FR - Francia 15
EU - Europa 14
VE - Venezuela 13
PK - Pakistan 12
PL - Polonia 10
PY - Paraguay 10
NL - Olanda 9
UY - Uruguay 8
AT - Austria 7
CH - Svizzera 7
CL - Cile 7
CZ - Repubblica Ceca 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
JO - Giordania 6
PE - Perù 6
RO - Romania 6
SA - Arabia Saudita 6
PS - Palestinian Territory 5
TN - Tunisia 5
AZ - Azerbaigian 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
EG - Egitto 4
HN - Honduras 4
JM - Giamaica 4
KE - Kenya 4
KZ - Kazakistan 4
RS - Serbia 4
AL - Albania 3
AO - Angola 3
DZ - Algeria 3
KH - Cambogia 3
LB - Libano 3
LV - Lettonia 3
PA - Panama 3
XK - ???statistics.table.value.countryCode.XK??? 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
KG - Kirghizistan 2
LT - Lituania 2
LU - Lussemburgo 2
MD - Moldavia 2
NP - Nepal 2
PR - Porto Rico 2
AN - Antille olandesi 1
BG - Bulgaria 1
BJ - Benin 1
BN - Brunei Darussalam 1
CV - Capo Verde 1
CY - Cipro 1
DJ - Gibuti 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
ME - Montenegro 1
Totale 21.679
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Woodbridge 1.736
Houston 1.142
Ann Arbor 968
Ashburn 895
Jacksonville 768
Seattle 713
Wilmington 677
Singapore 632
Cambridge 616
Chandler 543
Beijing 525
Dearborn 503
Hong Kong 486
Boardman 236
Princeton 197
Dublin 186
Munich 162
Udine 131
Izmir 111
Los Angeles 110
Dallas 104
San Diego 94
Ho Chi Minh City 86
Buffalo 74
São Paulo 67
Hefei 65
Redondo Beach 59
New York 57
Seoul 56
Helsinki 52
Hanoi 47
Ogden 47
Des Moines 43
Nanjing 37
Norwalk 36
Ottawa 35
Santa Clara 30
Turku 29
Kunming 28
Dong Ket 25
Florence 25
Rio de Janeiro 24
Mumbai 23
Brussels 18
Guangzhou 18
Andover 17
Trieste 17
Johannesburg 16
Saint Petersburg 16
Tokyo 16
Belo Horizonte 15
Boston 15
Curitiba 15
Montreal 15
Jinan 14
Shenyang 14
Falls Church 12
Leawood 12
Bogotá 11
Lappeenranta 11
Nanchang 11
San Mateo 11
Shanghai 11
Toronto 11
Atlanta 10
Brasília 10
Poplar 10
Warsaw 10
Ardabil 9
Baghdad 9
Brooklyn 9
Haiphong 9
Recife 9
Stockholm 9
Chengdu 8
Chennai 8
Goiânia 8
Grafing 8
Nuremberg 8
Phoenix 8
Porto Alegre 8
San Francisco 8
Simi Valley 8
Campinas 7
Charlotte 7
Frankfurt am Main 7
Fremont 7
Guarulhos 7
Mexico City 7
Salvador 7
Tashkent 7
The Dalles 7
Venezia 7
Amman 6
Da Nang 6
Denver 6
Dhaka 6
Fuzhou 6
Indiana 6
Totale 14.867
Salva come PNG Salva come JPEG
Nome #
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 214
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 193
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 183
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 183
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 182
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 178
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 171
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 163
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 163
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 163
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 161
Management of immune thrombocytopenia in elderly patients 160
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. 157
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 156
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 155
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 155
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma 154
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 153
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 153
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 153
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 153
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia. 149
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 149
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 149
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 146
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 146
More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. 145
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 145
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 141
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 141
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 141
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 141
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 140
Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. 139
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 139
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 138
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 138
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 137
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 136
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 135
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 134
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. 133
Peripheral T-cell lymphoma unspecified PTCL-U): a new prognostic model from a retrospective multicentric clinical study 133
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 133
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 133
The role of Rituximab in the therapy of mixed cryoglobulinemia 132
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 132
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 131
Rituximab for the treatment of type II mixed cryoglobulinemia 130
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 130
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 129
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. 129
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 129
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. 128
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 128
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. 127
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 127
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 126
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 126
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 126
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 125
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 124
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma 124
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 124
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 124
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. 124
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 124
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 123
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 122
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. 122
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 122
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 122
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. 122
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 122
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 121
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. 121
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 121
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 121
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 121
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. 120
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 119
Rituximab-responsive CIDP. 119
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. 118
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. 118
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 118
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 118
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 117
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. 117
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 116
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 116
HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. 115
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients 115
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 115
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 114
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. 114
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: A proposal for clinical application 114
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 113
Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. 113
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. 113
Temozolomide as salvage treatment in primary brain lymphomas 112
Totale 13.557
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.454
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.778 0 0 0 0 0 357 187 328 315 119 300 172
2021/20221.580 57 183 71 109 52 78 100 87 15 261 303 264
2022/20231.323 214 72 20 135 141 398 0 91 171 18 34 29
2023/2024381 60 22 10 14 69 46 22 14 65 25 15 19
2024/20253.199 52 252 154 66 120 168 214 204 342 261 466 900
2025/20262.955 378 649 501 523 825 79 0 0 0 0 0 0
Totale 22.147